DC
ARKG icon

Davenport & Co’s ARK Genomic Revolution ETF ARKG Stock Holding History

Davenport & Co’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$861K Buy
20,464
+373
+2% +$11.9K ﹤0.01% 825
2026
Q1 		$531K Buy
20,091
+322
+2% +$9.43K ﹤0.01% 912
2025
Q4 		$573K Sell
19,769
-86
-0.4% -$2.58K ﹤0.01% 859
2025
Q3 		$551K Sell
19,855
-287
-1% -$7.25K ﹤0.01% 868
2025
Q2 		$490K Sell
20,142
-75
-0.4% -$1.64K ﹤0.01% 881
2025
Q1 		$420K Buy
20,217
+838
+4% +$21.1K ﹤0.01% 891
2024
Q4 		$456K Buy
19,379
+150
+0.8% +$3.69K ﹤0.01% 873
2024
Q3 		$492K Sell
19,229
-1,591
-8% -$40.5K ﹤0.01% 830
2024
Q2 		$489K Buy
20,820
+173
+0.8% +$4.37K ﹤0.01% 806
2024
Q1 		$594K Buy
20,647
+1,018
+5% +$30.6K ﹤0.01% 756
2023
Q4 		$644K Buy
19,629
+200
+1% +$5.44K ﹤0.01% 696
2023
Q3 		$541K Buy
19,429
+38
+0.2% +$1.24K ﹤0.01% 703
2023
Q2 		$661K Sell
19,391
-60
-0.3% -$1.89K ﹤0.01% 672
2023
Q1 		$585K Sell
19,451
-18
-0.1% -$558 ﹤0.01% 676
2022
Q4 		$550K Sell
19,469
-1,076
-5% -$34.1K ﹤0.01% 657
2022
Q3 		$675K Sell
20,545
-92
-0.4% -$3.38K 0.01% 594
2022
Q2 		$650K Sell
20,637
-117
-0.6% -$4.09K 0.01% 607
2022
Q1 		$953K Sell
20,754
-1,332
-6% -$63.5K 0.01% 561
2021
Q4 		$1.35M Sell
22,086
-91
-0.4% -$6.29K 0.01% 497
2021
Q3 		$1.66M Buy
22,177
+614
+3% +$51.5K 0.01% 426
2021
Q2 		$2M Sell
21,563
-723
-3% -$61.5K 0.02% 333
2021
Q1 		$1.98M Sell
22,286
-2,421
-10% -$240K 0.02% 283
2020
Q4 		$2.3M Buy
24,707
+87
+0.4% +$6.93K 0.02% 256
2020
Q3 		$1.57M Sell
24,620
-678
-3% -$39.7K 0.02% 272
2020
Q2 		$1.32M Buy
25,298
+1,558
+7% +$66.8K 0.02% 288
2020
Q1 		$743K Buy
23,740
+6,200
+35% +$207K 0.01% 340
2019
Q4 		$588K Buy
17,540
+4,030
+30% +$128K 0.01% 439
2019
Q3 		$466K Sell
13,510
-600
-4% -$19.5K 0.01% 460
2019
Q2 		$486K Buy
14,110
+3,185
+29% +$102K 0.01% 450
2019
Q1 		$359K Buy
10,925
+1,250
+13% +$36.9K ﹤0.01% 500
2018
Q4 		$232K Buy
9,675
+1,200
+14% +$33.8K ﹤0.01% 563
2018
Q3 		$283K Buy
8,475
+1,075
+15% +$34K ﹤0.01% 568
2018
Q2 		$215K Buy
+7,400
New +$206K ﹤0.01% 632

Other funds holding ARKG

MFPI
Midwest Financial Partners Investments St. Cloud, Minnesota $241M AUM
CIC
Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return
CFIM
Client First Investment Management West Bend, Wisconsin $237M AUM 90.28% 1-Year Est. Return
BCM
Brookstone Capital Management Wheaton, Illinois $9.99B AUM 23.61% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
WAP
Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return
PRTG
Post Resch Tallon Group Pittsford, New York $145M AUM 25.19% 1-Year Est. Return
PWM
Purus Wealth Management Newport Beach, California $363M AUM 39.16% 1-Year Est. Return
LW
Lauer Wealth Valparaiso, Indiana $167M AUM 23.59% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Davenport & Co's ARKG Position: Q2 2026 in Review

Davenport & Co increased its ARK Genomic Revolution ETF (ARKG) stake by 1.9% in Q2 2026, buying an estimated $11.9K and bringing the position to 20,464 shares worth $861K. The position accounts for ﹤0.01% of the portfolio, ranked #825.

Davenport & Co first reported a position in ARKG in Q2 2018 and has held it in 33 quarters since. The position peaked at $2.3M in Q4 2020. 45 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • Davenport & Co held 20,464 shares of ARK Genomic Revolution ETF worth $861K as of Q2 2026.
  • Davenport & Co bought 373 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $11.9K.
  • ARK Genomic Revolution ETF made up ﹤0.01% of Davenport & Co's portfolio in Q2 2026, its #825 holding.
  • Davenport & Co first reported a position in ARK Genomic Revolution ETF in Q2 2018 and has held it in 33 quarters since.
  • Davenport & Co's ARK Genomic Revolution ETF position peaked at $2.3M in Q4 2020.
  • 45 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.